

**From:** [REDACTED] (CAB-BIENKOWSKA)  
**Sent:** Monday 19 March 2018 14:09  
**To:** CAB BIENKOWSKA ARCHIVES  
**Subject:** FW: IP Incentives analysis & SPCs - Meeting request with EFPIA

**From:** Nathalie Moll [[mailto:\[REDACTED\]](mailto:[REDACTED])]  
**Sent:** Monday, March 19, 2018 2:00 PM  
**To:** [REDACTED] (CAB-BIENKOWSKA)  
**Cc:** [REDACTED] (CAB-BIENKOWSKA); [REDACTED]  
**Subject:** IP Incentives analysis & SPCs - Meeting request with EFPIA

Dear Mr Husak,

I am contacting you in my capacity of Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) regarding the currently ongoing analysis of intellectual property incentives related to the pharmaceutical sector. EFPIA represents 1,900 pharmaceutical innovative companies committed to researching, developing and bringing new therapies to patients that will improve their health and quality of life while positively contributing to the EU economy.

The ongoing analysis and most notably the discussions on amending the framework for Supplementary Protection Certificates (SPCs), are of utmost importance to our industry. Intellectual Property including SPCs are imperative for fostering and safeguarding the significant investments in research and development of new and innovative medicines.

I would like to follow up on the initial discussion a delegation of our Board held with Commissioner Bieńkowska on 30th January 2018 with regard to the recent swift developments in relation to the SPC. Having followed the process closely, the innovative industry has reacted to the various positions and arguments that have been brought forward and we have developed our views further as EFPIA. We have identified a possible option that could be supported by all stakeholders involved and hope that this could allow for it to be considered in the final stages of decision making.

I would be most appreciative if we could discuss this matter further during a personal meeting at your earliest convenience and will of course adapt to your availabilities.

Thank you in advance for your time and kind consideration.

Yours sincerely,

Nathalie Moll

**Nathalie Moll**

**Director General**

EFPIA - European Federation of Pharmaceutical Industries and Associations  
Leopold Plaza Building  
Rue du Trône 108  
B-1050 Bruxelles

Tel: [+3226262540](tel:+3226262540) (Direct Line)

Tel: [+3226262555](tel:+3226262555) (Switchboard)

Email: [nathalxx.xxxx@xxxxx.xx](mailto:nathalxx.xxxx@xxxxx.xx)

[www.efpia.eu](http://www.efpia.eu)

